Our findings correlate with data in the literature when it was shown that WT1 is overexpressed in mRNR and protein levels in solid cancers, such as brain, breast, cervical, colon, glioblastoma, and others, and blood cancers, such as acute and chronic leukemia, myeloma, and myelodysplastic syndrome (Silberstein et al., 1997). This evidence concerns the gene WT1 and hematopoietic and lymphoid system neoplasm.